ClinicalTrials.gg
RecruitingNCT07545642Updated Jun 24, 2026

Effect of Lateral Versus Supine Positions on Postoperative Hypoxemia

An interventional study of Lateral decubitus position group (Group L) and Supine position group (Group S) in Postoperative Hypoxemia, sponsored by General Hospital of Ningxia Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 97 studies in Hypoxia with a site in China — 44 open to participants now, 45 under way, none of them phase 3. Hypoxia · China.

Planned enrollment
13th of 78
960 · median 240
Started
2026
with 18 others
No phase
63 of 97
31 open now
Primary completion
2026-06
later than 20 of 44 live
Registered
80th of 97
by date
Lead sponsor
3 of 97
General Hospital of Ningxia Medical University

Among the 97 studies in Hypoxia with a site in China, this one is the 13th largest by planned enrollment of the 78 interventional ones that give a count, is one of 19 that started in 2026, is one of 63 with no phase, reaches primary completion later than 20 of the 44 other live ones, and was the 80th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

44 of the 97 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Hypoxia with a site in China, or all of them as a file.
02

Study summary

Using prospective real-world data, this study aims to determine whether the lateral decubitus position reduces the incidence of post-procedure hypoxemia in patients undergoing painless gastroscopy/colonoscopy, thereby providing a simple, non-invasive, and low-cost optimization strategy for clinical practice.

Read the detailed description

Painless gastroscopy and colonoscopy have become essential modalities for the screening and diagnosis of digestive tract diseases, with their utilization increasing annually. However, hypoxemia remains the most common complication during these procedures, with reported incidences ranging widely from 1.8% to 69%. Severe hypoxemia can lead to adverse outcomes, including arrhythmias, hemodynamic decompensation, and hypoxic brain injury. Consequently, developing effective strategies to prevent hypoxemia in patients undergoing sedation for gastrointestinal (GI) endoscopy is of significant clinical value.

Current clinical research has primarily focused on hypoxemia occurring during the endoscopic procedure itself, whereas there is a paucity of high-quality evidence regarding the incidence and preventive measures of hypoxemia during the recovery phase. Specifically, the impact of body positioning on post-procedural hypoxemia remains largely unexplored. Emerging evidence suggests that the lateral decubitus position significantly reduces the incidence of hypoxemia during adult sedation. Anatomically, in the supine position, residual sedative effects combined with gravity cause the tongue and soft palate-structures lacking bony support-to collapse posteriorly, leading to upper airway obstruction. Conversely, the lateral position helps maintain a patent airway by preventing this collapse and optimizing the ventilation-perfusion (V/Q) matching, thereby stabilizing oxygenation.

Despite this theoretical basis, prospective studies investigating the effect of body positioning on recovery-phase hypoxemia in real-world settings are lacking. Therefore, this study hypothesizes that the lateral decubitus position reduces the incidence of recovery-phase hypoxemia compared to the supine position. Using prospective real-world data, we aim to validate this hypothesis and provide a simple, non-invasive, and cost-effective optimization strategy for clinical practice.

03

Conditions studied

  • Postoperative Hypoxemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Both sexes.
  3. (ASA) physical status classification I-III.
  4. Scheduled for combined painless esophagogastroduodenoscopy/colonoscopy or either of the two procedures.
  5. Ability to understand the study protocol and provide written .
  6. A broad set of inclusion criteria was adopted to enroll a patient population that better reflects routine clinical practice. The study aimed to enhance the generalizability of the findings by including patients with various comorbidities, such as preprocedural hypoxemia (room-air SpO₂ ≤ 90%), history of pulmonary surgery, obstructive sleep apnea (OSA), and other pulmonary conditions (including asthma, , chronic bronchitis, emphysema, and pulmonary bullae).

Exclusion criteria

Exclusion Criteria:

  1. Severe cardiovascular or cerebrovascular diseases.
  2. Pregnant patients.
  3. History of to ciprofol.

Withdrawal Criteria:

  1. Endotracheal intubation required during the procedure.
  2. Voluntary withdrawal requested by the patient or their legal representative.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    Supine position group (Group S)

    The patient was turned from the predetermined left lateral position to the supine position without a head pillow (head-of-bed elevation at 0 degrees)

    Procedure: Supine position group (Group S)

  • Experimental
    Lateral decubitus position group (Group L)

    Upon arrival in the post-anesthesia care unit (PACU), the patient was kept in the left lateral decubitus position

    Procedure: Lateral decubitus position group (Group L)

Interventions

  • ProcedureLateral decubitus position group (Group L)

    Upon admission to the Post-Anesthesia Care Unit (PACU), an independent researcher (attending anesthesiologist) assessed the patient using the Ramsay Sedation Scale (1: anxious and agitated; 2: awake, calm, and cooperative; 3: drowsy but responsive to verbal commands; 4: asleep but responsive to tactile stimulation or pain; 5: asleep with a sluggish response to stimulation; 6: deep sleep with no response). Patients in the Lateral Group (Group L) were maintained in the predetermined left lateral position. Standard monitoring was applied, and nasal cannula oxygen was administered at 2 L/min. If SpO₂ remained \>95% for at least 5 minutes, oxygen was discontinued for observation. To ensure strict adherence to the protocol, an independent researcher continuously monitored and verified patient positioning (corrections were made only if the patient rolled unconsciously). Patients were evaluated using the Aldrete discharge scoring system; discharge from the PACU occurred when a score of \>9 was a

  • ProcedureSupine position group (Group S)

    Upon admission to the Post-Anesthesia Care Unit (PACU), an independent researcher (attending anesthesiologist) assessed the patient using the Ramsay Sedation Scale (1: anxious and agitated; 2: awake, calm, and cooperative; 3: drowsy but responsive to verbal commands; 4: asleep but responsive to tactile stimulation or pain; 5: asleep with a sluggish response to stimulation; 6: deep sleep with no response). Patients in the Supine Group (Group S) were turned from the predetermined lateral position to the supine position without a head pillow (head-of-bed elevation at 0 degrees). Standard monitoring was applied, and nasal cannula oxygen was administered at 2 L/min. If SpO₂ remained \>95% for at least 5 minutes, oxygen was discontinued for observation. To ensure strict adherence to the protocol, an independent researcher continuously monitored and verified patient positioning (corrections were made only if the patient rolled unconsciously). Patients were evaluated using the Aldrete discharge

06

What researchers measure

Primary outcomes

  1. Incidence of recovery-phase hypoxemia,

    Proportion of participants experiencing hypoxemia (SpO₂ ≤ 90% lasting \>10 seconds) during the post-procedure recovery period.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

Secondary outcomes

  1. Incidence of Severe Hypoxemia During Recovery

    Proportion of participants experiencing severe hypoxemia, defined as pulse oxygen saturation (SpO₂) \< 85% lasting \>10 seconds during the post-procedure recovery period.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  2. Incidence of Subclinical Respiratory Depression during Recovery

    Proportion of participants experiencing subclinical respiratory depression, defined as any episode of pulse oxygen saturation (SpO₂) in the range of 90% to \<95% (inclusive of 90%, exclusive of 95%) during the post-procedure recovery period.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes.

  3. Overall Incidence of Airway Intervention During Recovery

    Proportion of participants requiring any grade of airway intervention (increase oxygen flow, chin lift, mask ventilation, or reintubation) during recovery.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  4. Cough Severity Grade During Recovery

    Severity of cough assessed during the recovery period, graded as: Grade I: No cough, smooth breathing; Grade II: Single mild cough; Grade III: Multiple coughs lasting \<15 seconds; Grade IV: Continuous coughing lasting ≥15 seconds. Reported as the proportion of participants reaching each grade (I-IV).

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  5. Length of Stay in Post-Anesthesia Care Unit (PACU)

    Time from admission to the post-anesthesia care unit (PACU) until discharge criteria are met (modified Aldrete score ≥9 on three consecutive assessments), recorded in minutes.

    Time frame: From PACU admission until discharge

  6. Respiratory Comfort Score During Recovery

    Patient-reported respiratory comfort assessed using a Numerical Rating Scale (NRS) ranging from 0 (worst discomfort) to 10 (greatest comfort)

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  7. PACU Nurse Satisfaction Score

    Nurse-assessed satisfaction with patient respiratory stability and overall recovery management, rated using a Numerical Rating Scale (NRS) ranging from 0 (lowest satisfaction) to 10 (highest satisfaction), recorded at patient discharge from the post-anesthesia care unit.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  8. Incidence of Tachycardia During Recovery

    Proportion of participants experiencing tachycardia (heart rate \>100 beats/min) during the post-procedure recovery period.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  9. Incidence of Bradycardia During Recovery

    Proportion of participants experiencing bradycardia (heart rate \<50 beats/min) during recovery.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  10. Incidence of Hypotension During Recovery

    Proportion of participants experiencing hypotension (systolic blood pressure \<80 mmHg) during recovery.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  11. Incidence of Nausea or Vomiting During Recovery

    Proportion of participants experiencing nausea (subjective complaint) or vomiting (objective expulsion of gastric contents) during recovery.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

  12. Incidence of Laryngospasm During Recovery

    Proportion of participants experiencing laryngospasm (acute upper airway obstruction with stridor/inability to ventilate, resolving with intervention) during recovery.

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

Other outcomes

  1. Prespecified Subgroup Analyses

    Subgroup analyses will be conducted to explore heterogeneity of treatment effects on the primary outcome (incidence of recovery-phase hypoxemia) across baseline categories: Demographics: age (\<65 vs ≥65 years), sex, body mass index (BMI) category; Clinical characteristics: ASA physical status (I-II vs III), smoking/alcohol history, Mallampati classification (I-II vs III-IV); Procedural factors: endoscopy type (gastroscopy vs colonoscopy vs combined), preprocedural hypoxemia (room-air SpO₂ ≤90%), history of pulmonary surgery, obstructive sleep apnea (OSA), respiratory comorbidities (asthma/COPD/chronic bronchitis/emphysema/bullae), and intraprocedural hypoxemia (SpO₂ ≤90% \>10 s); Postprocedural sedation: Ramsay Sedation Score (2-6). Effect modification will be tested using interaction terms in regression models (or stratified analysis with Cochran-Mantel-Haenszel test).

    Time frame: From PACU admission until discharge, assessed up to 30 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Jun 2026, 1 month.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 1 month is below that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 22, 2026
StartActual
Apr 22, 2026
Primary completionActual
Jun 18, 2026
CompletionEst.
Jul 30, 2026
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07545642
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 22, 2026
Primary completion
Jun 18, 2026
Completion
Jul 30, 2026 (estimated)
Last update
Jun 24, 2026

Study contacts

Xiaoyong Wei, Degree
Contact
weixy9912@126.com
86-951-674-3252
Xinli Ni, Doctoral
study chair · 86-951-674-3252

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion